Bijblijven

, Volume 29, Issue 8, pp 56–68 | Cite as

Atriumfibrilleren

  • W. Lucassen
  • W. Opstelten
Artikelen
  • 166 Downloads

Samenvatting

Atriumfibrilleren is een frequent voorkomende ritmestoornis. Ook zonder aanwezigheid van klachten is het belangrijk atriumfibrilleren te herkennen, omdat het tot ernstige complicaties kan leiden, in het bijzonder een ischemisch CVA. Screening in de huisartsenpraktijk van hoogrisicopatiënten zou daarom weleens nuttig kunnen zijn. Om het risico op een ischemisch CVA te bepalen, is er een nieuwe risicoscore ontwikkeld (CHA2DS2-VASc).

Bij vrijwel alle oudere patiënten (> 65jaar) zijn nu orale anticoagulantia geïndiceerd. Acetylsalicylzuur is alleen nog geïndiceerd bij een contra-indicatie voor orale anticoagulantia. De nieuwe orale anticoagulantia vormen een belangrijke ontwikkeling in de antitrombotische behandeling bij atriumfibrilleren, maar hebben vooralsnog een zeer beperkte plaats in de huisartsenpraktijk.

Literatuur

  1. 1.
    NHG-werkgroep Atriumfibrilleren. NHG-Standaard Atriumfibrilleren (tweede partie¨le herziening).Huisarts en wetenschap 2013;56(7).Google Scholar
  2. 2.
    Langenberg M, Hellemons BS, Ree JW van, Vermeer F, Lodder J, Schouten HJ, et al. Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice. BMJ 1996 Dec 14; 313(7071):1534.CrossRefPubMedGoogle Scholar
  3. 3.
    Heeringa J, Kuip DA van der, Hoffman A, Kors JA, Herpen G van, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006 Apr;27(8): 949–53.CrossRefPubMedGoogle Scholar
  4. 4.
    Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994 Mar 16;271(11):840–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997 Oct 7;96(7):2455–61.CrossRefPubMedGoogle Scholar
  6. 6.
    Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR, Jr., Ilstrup DM, et al. The natural history of lone atrial fibrillation. A populationbased study over three decades. New Engl J Med 1987 Sep 10;317(11):669–74.CrossRefPubMedGoogle Scholar
  7. 7.
    Sudlow M, Rodgers H, Kenny RA, Thomson R. Identification of patients with atrial fibrillation in general practice: a study of screening methods. BMJ 1998 Aug 1;317(7154):327–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Morgan S, Mant D. Randomised trial of two approaches to screening for atrial fibrillation in UK general practice. Br J Gen Pract 2002 May; 52(478):373–80.PubMedGoogle Scholar
  9. 9.
    Schilte B, Hellemons-Boode B, Zwietering PJ. Palpatie van de pols bij atriumfibrilleren vergeleken met het ECG. Huisarts Wet 1997;40:95–7.Google Scholar
  10. 10.
    Mant J, Fitzmaurice DA, Hobbs FD, Jowett S, Murray ET, Holder R, et al. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ 2007 Aug 25;335(7616):380.CrossRefPubMedGoogle Scholar
  11. 11.
    Sandercock P, Bamford J, Dennis M, Burn J, Slattery J, Jones L, et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project). BMJ 1992 Dec 12;305(6867):1460–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Berg PJ van den. Preventive care. Studies on cardiovascular disease and hearing loss (proefschrift). Rotterdam: Erasmus Universiteit Rotterdam, 1999.Google Scholar
  13. 13.
    Sudlow M, Rodgers H, Kenny RA, Thomson R. Population based study of use of anticoagulants among patients with atrial fibrillation in the community. BMJ 1997 May 24;314(7093):1529–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Hill JD, Mottram EM, Killeen PD. Study of the prevalence of atrial fibrillation in general practice patients over 65 years of age. J R Coll Gen Pract 1987 Apr;37(297):172–3.PubMedGoogle Scholar
  15. 15.
    Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007 Aug 25;335(7616):383.CrossRefPubMedGoogle Scholar
  16. 16.
    Verberk WJ, Leeuw PWde. Accuracy of oscillometric blood pressure monitors for the detection of atrial fibrillation: a systematic review. Expert Rev Med Devices 2012 Nov;9(6):635–40.CrossRefPubMedGoogle Scholar
  17. 17.
    Reiffel JA, Schwarzberg R, Murry M. Comparison of autotriggered memory loop recorders versus standard loop recorders versus 24-hour Holter monitors for arrhythmia detection. Am J Cardiol 2005 May 1;95(9):1055–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Hoes AW, Voors AA, Rutten FH, Lieshout J van, Janssen PGH, Walma EP. NHG-Standaard Hartfalen (tweede herziening). Huisarts Wet 2010; 53(7):368–9.Google Scholar
  19. 19.
    de DS, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005 Feb 14;165(3):258–62.CrossRefGoogle Scholar
  20. 20.
    Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, Essebag V, Eisenberg MJ, Wynant W, et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med 2012 Jul 9;172(13):997–1004.CrossRefPubMedGoogle Scholar
  21. 21.
    Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. New Engl J Med 2008 Jun 19;358(25):2667–77.CrossRefPubMedGoogle Scholar
  22. 22.
    Wolf PA, Dawber TR, Thomas HE, Jr., Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978 Oct;28(10):973–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010 Feb;137(2):263–72.CrossRefPubMedGoogle Scholar
  24. 24.
    Staa TP van, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 2011 Jan;9(1): 39–48.CrossRefPubMedGoogle Scholar
  25. 25.
    Hobbs FD, Roalfe AK, Lip GY, Fletcher K, Fitzmaurice DA, Mant J. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ 2011;342:d3653.CrossRefPubMedGoogle Scholar
  26. 26.
    Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989 Jan 28;1(8631):175–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. New Engl J Med 1990 Mar 22;322(12):863–8.Google Scholar
  28. 28.
    Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007 Jun 19;146(12):857–67.CrossRefPubMedGoogle Scholar
  29. 29.
    Walraven C van, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009 Apr;40(4):1410–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012 May 15;125(19): 2298–307.CrossRefPubMedGoogle Scholar
  31. 31.
    Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007 Aug 11;370(9586):493–503.CrossRefPubMedGoogle Scholar
  32. 32.
    Engelfriet PM, Briet E. Introductie van nieuwe antistollingsmiddelen. Ned Tijdschr Geneeskd 2012;156:A5203.Google Scholar
  33. 33.
    Federatie van Nederlandse trombosediensten. Samenvatting medisch jaarverslag 2011.Google Scholar
  34. 34.
    Bloomfield HE, Krause A, Greer N, Taylor BC, MacDonald R, Rutks I, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med 2011 Apr 5;154(7):472–82.CrossRefPubMedGoogle Scholar
  35. 35.
    Levi M. Zelfmanagement van antistolling leidt tot betere overleving en minder thrombo-embolische complicaties. Ned Tijdschr Geneeskd 2011; 154:A3574.Google Scholar
  36. 36.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009 Sep 17;361(12):1139–51.CrossRefPubMedGoogle Scholar
  37. 37.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011 Sep 8;365(10):883–91.CrossRefPubMedGoogle Scholar
  38. 38.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011 Sep 15;365(11):981–92.CrossRefPubMedGoogle Scholar
  39. 39.
    Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012 Aug 1;110(3):453–60.CrossRefPubMedGoogle Scholar
  40. 40.
    Adam SS, McDuffie JR, Ortel TL, Williams JW, Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012 Dec 4; 157(11):796–807.CrossRefPubMedGoogle Scholar
  41. 41.
    Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: metaanalysis of noninferiority randomized controlled trials. Arch Intern Med 2012 Mar 12;172(5):397–402.CrossRefPubMedGoogle Scholar
  42. 42.
    Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010 Sep 18; 376(9745):975–83.CrossRefPubMedGoogle Scholar
  43. 43.
    Leebeek FW, Kamphuisen PW. [The new oral anticoagulant in the Netherlands.] Ned Tijdschr Geneeskd 2009 Apr 18;153(16):773–7.PubMedGoogle Scholar
  44. 44.
    Dijk EJ van, Koudstaal PJ, Roos YB, Brouwers PJ, Kappelle LJ. [New oral anticoagulants for atrial fibrillation: a neurologist’s view.] Ned Tijdschr Geneeskd 2012;156(39):A5283.PubMedGoogle Scholar

Copyright information

© Bohn, Stafleu van Loghum 2013

Authors and Affiliations

  • W. Lucassen
    • 1
  • W. Opstelten
    • 2
  1. 1.postdoc AMCAmsterdamThe Netherlands
  2. 2.NHGUtrechtThe Netherlands

Personalised recommendations